Bacteriophage Therapy for Drug-Resistant Endophthalmitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotic therapies are ineffective against drug-resistant bacteria, particularly in treating bacterial endophthalmitis, which can lead to rapid tissue destruction and permanent vision loss due to the lack of rapid bacterium elimination and high toxicity concerns.
Innovation Solution
Development of novel bacteriophages, specifically phiEF7H, phiEF19G, and phiEF14H1, which exhibit broad bacteriolytic action against Enterococcus strains causing endophthalmitis, offering a targeted and low-toxicity treatment alternative that can be administered intravenously or topically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat bacterial endophthalmitis, then bacterial infection can be suppressed, but drug-resistant bacteria emerge and treatment effectiveness decreases
Solution Approach 1:
Bacteriophages serve as intermediary agents that specifically infect and lyse bacterial cells causing endophthalmitis. The phages act as a mediator between the treatment goal and the pathogen, providing antibacterial activity through biological infection rather than chemical inhibition, thereby avoiding the development of drug resistance associated with conventional antibiotics
Solution Approach 2:
The patent replaces the chemical mechanism of antibiotic action with a biological mechanism using bacteriophages. Instead of using chemical substances that can be degraded or induce resistance, the treatment employs living viral particles that replicate and propagate within the infection site, providing sustained therapeutic effect without resistance development
2Productivity
If high doses of antibiotics are administered to rapidly eliminate bacteria, then bacterial load decreases, but tissue toxicity and damage increase
Solution Approach 1:
Bacteriophages exhibit local specificity by targeting only the infected tissue where the bacterial infection is present. The phages replicate and accumulate at the infection site, providing high local concentration of antibacterial activity exactly where needed, while maintaining low systemic toxicity to healthy tissues throughout the body
Solution Approach 2:
The bacteriophage system is self-amplifying at the infection site. Upon administration, the phages infect bacterial cells and replicate, automatically increasing their own concentration where the bacteria are present. This self-service mechanism ensures adequate therapeutic dosage is achieved locally without requiring high initial systemic doses that would cause tissue toxicity
3Adaptability or versatility
If conventional antibiotics are used, then broad-spectrum coverage is achieved, but non-pathogenic bacteria are also affected causing opportunistic infections
Solution Approach 1:
Each bacteriophage preparation is highly specific to its target bacterial species or strain, acting like a lock-and-key system. The phages only infect and replicate within their specific host bacteria, leaving all other bacteria in the body completely unaffected. This localized specificity provides targeted therapy that spares the normal microbiota, preventing opportunistic infections while still achieving effective coverage of the pathogen
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These bacteriophages effectively reduce bacterial loads and inflammation in endophthalmitis models, demonstrating potential for rapid bacterial elimination and minimizing tissue damage, even against drug-resistant strains, with low toxicity and high specificity.
Implementation Method 1
a bacteriophage has higher specificity than antibiotics and does not exhibit a bacteriolytic action to bacteria other than a specific bacterium
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The objective of the present invention is to provide a novel bacteriophage useful for treating bacterial endophthalmitis and a therapeutic agent for bacterial endophthalmitis comprising the novel bacteriophage. The therapeutic agent for bacterial endophthalmitis according to the present invention is characterized in comprising 1 or more bacteriophages selected from the group essentially consisting of Myoviridae Spounavirinae phiEF7H (accession number: NITE BP-02886), Myoviridae Spounavirinae phiEF19G (accession number: NITE BP-02887), Myoviridae Spounavirinae phiEF14H1 (accession number: NITE BP-02888), and mutants thereof.